Dyadic International, Inc.

As of March 27, 2019, Dyadic International, Inc. is considered a risky investment due to its high Price to Book Value of 41.92, negative earnings ratios, and a significant decline in stock performance, with a year-to-date return of -43.91% and a five-year decline of -87.82%.

As of March 27, 2019, Dyadic International, Inc. is considered overvalued and risky due to extremely negative financial ratios, including a price-to-book value of 41.92 and a return on equity of -582.71%, alongside a year-to-date stock return of -46.40%, significantly underperforming the S&P 500.

As of May 13, 2025, Dyadic International, Inc. is in a bearish trend, indicated by a bearish MACD, moving averages, and KST across multiple time frames, along with Bollinger Bands showing a bearish condition.

As of March 2022, the management team of Dyadic International, Inc. includes Michael Tarnok (Independent Chairman), Mark Emalfarb (CEO), and several independent directors: Arindam Bose, Barry Buckland, Seth Herbst, Jack Kaye, and Patrick Lucy.

Dyadic International, Inc. is a biotechnology company that develops and licenses its C1 platform for pharmaceutical applications in human and animal markets. As of March 2025, it has a market cap of $38.96 million, with net sales of $0 million and a net loss of $2 million.

As of Jun 18, Dyadic International, Inc. has a market capitalization of 38.96 million and reported net sales of 3.56 million with a net profit of -5.83 million over the latest four quarters. Shareholder's funds are at 2.47 million and total assets at 9.93 million.